Vertex Pharma (VRTX) Tops Q1 EPS by 4c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Vertex Reports First Quarter 2022 Financial Results
May 5, 2022 4:01 PM EDTProduct revenues of $2.10 billion, a 22% increase compared to Q1 2021
Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion
Mid- and late-stage clinical pipeline now spans 6 disease areas
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results... More
